Advertisement

Neuroprotective Effects of MAO-B Inhibition: Clinical Studies in Parkinson’s Disease

  • P. A. LeWitt
Chapter
Part of the Milestones in Drug Therapy book series (MDT)

Abstract

Parkinson’s Disease (PD), characterized by a marked loss of nigrostriatal neurons [1], is generally a disorder of progressive disability. While additional neuronal systems of the PD brain are altered [2], the change most closely linked to the clinical symptomatology of Parkinsonism is the impaired generation of striatal dopamine. Dopamine production may also figure in the special vulnerability of substantia nigra pars compacta neurons in PD. Several hypotheses for the decline in dopaminergic neurons have been advanced. One speculation has been that one or more exogenous toxins might produce a metabolic effect damaging these neurons. Several neurotoxins with highly specific actions against nigrostriatal dopaminergic neurons are known. These produce parkinsonian symptomatology both in animal models and, in the case of manganese and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), in man. MPTP has been the most intriguing of these because of its need for conversion in the brain prior to exerting toxicity to nigrostriatal dopamine neurons via their mitochondrial metabolism. The unique properties of MPTP have provided grist for speculation that PD could conceivably be the outcome of intermittent or continuous neurotoxicity from exposure to similar types of compounds [3–5].

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    Forno LS. Pathology of Parkinson’s disease: the importance of the substantia nigra and Lewy bodies. In: Stern GM, editor. Parkinson’s Disease. Baltimore: Johns Hopkins Press 1990; 185–238.Google Scholar
  2. [2]
    Agid Y, Javoy-Agid F, Ruberg M. Biochemistry of neurotransmitters in Parkinson’s disease. In: Marsden CD, Fahn S, editors. Movement Disorders 2 . London: Butterworths 1987; 166–230.Google Scholar
  3. [3]
    Cohen G. Monoamine oxidase, hydrogen peroxide, and Parkinson’s Disease. Adv Neurol 1986; 45: 119–125.Google Scholar
  4. [4]
    Kopin IJ, Markey SP. MPTP toxicity: implications for research in Parkinson’s disease. Ann Rev Neurosci 1988; 11: 81–96.CrossRefGoogle Scholar
  5. [5]
    Ballard PA, Tetrud JW, Langston JW. Permanent human parkinsonism due to 1-methyl- 4-phenyl-l,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology 1985; 35: 949–956.CrossRefGoogle Scholar
  6. [6]
    Fornstedt B, Brun A, Rosengren E, Carlsson A. The apparent autoxidation rate of catechols in dopamine-rich regions of human brains increases with the degree of depigmentation of substantia nigra. J Neural Transm [P-D Sect] 1989; 1: 279–295.CrossRefGoogle Scholar
  7. [7]
    Spina MB, Cohen G. Exposure of striatal synaptosomes to L-dopa increases levels of oxidized gluthathione. J Pharmacol Exptl Therap 1988; 247: 502–507.Google Scholar
  8. [8]
    Halliwell B. Oxidants and the central nervous system: some fundamental questions. Acta Neurol Scand 1989; 126: 23–33.CrossRefGoogle Scholar
  9. [9]
    Adams JD, Odunze IN. Oxygen free radicals and Parkinson’s Disease. Free Radical Biol Med 1991; 10: 161–169.CrossRefGoogle Scholar
  10. [10]
    Halliwell B, Gutteridge JMC. Free Radicals in Biology and Medicine. Oxford: 1989; Oxford Press.Google Scholar
  11. [11]
    Mogi M, Harada M, Kiuchi K, Kojima K, Kondo T, Narabayashi H, Rausch D, Riederer P, Jellinger K, Nagatsu T. Homospecific activity (activity per enzyme protein) of tyrosine hydroxylase increases in Parkinson’s Disease. J Neural Transm 1988; 72: 77–81.CrossRefGoogle Scholar
  12. [12]
    Hornykiewicz O, Kish SJ. Biochemical pathophysiology of Parkinson’s Disease. Adv Neurol 1986; 45: 19–34.Google Scholar
  13. [13]
    Cohen G, Spina BM. Deprenyl suppresses the oxidant stress associated with increased dopamine turnover. Ann Neurol 1989; 26: 689–690.CrossRefGoogle Scholar
  14. [14]
    Kato T, Dong E, Iskii K, Kinemuchi H. Brain dialysis. In vivo metabolism of dopamine and serotonin by monoamine oxidase A but not B in the striatum of unrestrained rats. J Neurochem 1986; 48: 1277–1282.CrossRefGoogle Scholar
  15. [15]
    Dexter DT, Wells FR, Lees AJ, Agid Y, Jenner P, Marsden CD. Increased nigral iron content and alterations in other metals occurring in brain in Parkinson’s disease. J Neurochem 1989; 52: 1830–1836.CrossRefGoogle Scholar
  16. [16]
    Riederer P, Sofic E, Rausch WD et al. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 1989; 52: 515–520.CrossRefGoogle Scholar
  17. [17]
    Knoll J. The striatal dopamine dependency of life span in male rats. Longevity study with (-)deprenyl. Mech Ageing Devel 1988; 46: 237–262.CrossRefGoogle Scholar
  18. [18]
    Birkmayer W, Knoll J, Riederer P, Youdim MBH, Hars V, Marton J. Increased life-expectancy resulting from the addition of l-deprenyl to Madopar treatment in Parkinson’s disease: a longterm study. J Neural Transm 1985; 65: 113–127.CrossRefGoogle Scholar
  19. [19]
    The Parkinson Study Group: DATATOP: a multicenter controlled clinical trial in early Parkinson’s disease. Arch Neurol 1989; 46: 1052–1060.CrossRefGoogle Scholar
  20. [20]
    Le Witt PA, The Parkinson Study Group. Deprenyl’s protective effect against the progression of Parkinson’s Disease: the DATATOP study. Acta Neurol Scand 1991; 84 (Supplement 136): 79–86.Google Scholar
  21. [21]
    Riederer P, Youdim MB. Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl. J Neurochem 1986; 46: 1359–1365.CrossRefGoogle Scholar
  22. [22]
    Golbe LI. Deprenyl as symptomatic therapy in Parkinson’s disease. Clin Neuropharma- col 1988; 11: 387–400.CrossRefGoogle Scholar
  23. [23]
    The Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 1989; 321: 1364–1371.CrossRefGoogle Scholar
  24. [24]
    Tetrud JW, Langston JW. The effect of deprenyl (selegiline) on the natural history of Parkinson’s disease. Science 1989; 145: 519–522.CrossRefGoogle Scholar
  25. [25]
    Elizan TS, Yahr MD, Moros DA, Mendoza MR, Pang S, Bodian CA. Selegiline use to prevent progression of Parkinson’s disease. Experience in 22 de novo patients. Arch Neurol 1989; 46: 1275–1279.CrossRefGoogle Scholar
  26. [26]
    Teräväinen H. Selegiline in Parkinson’s disease. Acta Neurologica Scand 1990; 81: 333–336.CrossRefGoogle Scholar
  27. [27]
    Allain H, Cougnard J, Neukirch H-C, French Selegiline Multicenter Trial Members. Selegiline in de novo parkinsonian patients: The French Selegiline multicenter trial. Acta Neurol Scand 1991; 84 (Supplement 136): 73–78.CrossRefGoogle Scholar
  28. [28]
    Myllylä VV, Sotaniemi KA, Vuorinen JA, Heinonen EH. Selegiline as a primary treatment of Parkinson’s disease. Acta Neurol Scand 1991; 84 (Supplement 136): 70–72.CrossRefGoogle Scholar
  29. [29]
    LeWitt PA, Galloway MP, Matson W, Milbury P, McDermott M, Oakes D, The Parkinson Study Group. Markers of endogenous dopamine synthesis in Parkinson’s Disease. Neurology 1992; 42 (Supplement 3): 420.Google Scholar
  30. [30]
    Antelman SM, Edwards DJ, Lin M. Phenylethylamine: evidence for a direct, postsynaptic dopamine-receptor stimulatory action. Brain Res 1977; 127: 317–322.CrossRefGoogle Scholar
  31. [31]
    Jackson DM. 2-phenylethylamine, dopamine, and behaviour. In: Sandler M, Dahlstrom A, Belmaker RH, editors. Progress in catecholamine research. Part B: Central aspects. New York: Alan R Liss 1988; 429–432.Google Scholar
  32. [32]
    Robinson TE, Becker JB. Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res Rev 1986; 11: 157–198.CrossRefGoogle Scholar
  33. [33]
    Tatton WG, Greenwood CE. Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism. J Neurosci Res 1991; 30: 666–672.CrossRefGoogle Scholar
  34. [34]
    Da Prada M, Kettler R, Keller HH et al. From moclobemide to Ro 19–6327 and Ro 41–1049: the development of a new class of reversible, selective MAO-A and MAO-B inhibitors. J Neural Transm 1990; 29 (Supplement): 279–292.Google Scholar
  35. [35]
    LeWitt PA, Galloway MP. Neurochemical markers of Parkinson’s Disease. In: Koller WC, Paulson G, editors. Therapy of Parkinson’s Disease. New York: Marcel Dekker 1990; 63–93.Google Scholar
  36. [36]
    Hyman C, Hofer M, Barde Y-A et al. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 1990; 350: 230–232.CrossRefGoogle Scholar

Copyright information

© Springer Basel AG 1993

Authors and Affiliations

  • P. A. LeWitt

There are no affiliations available

Personalised recommendations